.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AF01_Zidovudine.Zidovudine

Information

Zidovudine (AZT) is a nucleoside reverse transcriptase inhibitor (NRTI) used primarily in the treatment and prevention of HIV infection. It was the first antiretroviral drug approved for use against HIV and is still used today, most often as part of combination antiretroviral therapy (ART).

Pharmacokinetics

Pharmacokinetic parameters are reported for healthy adult individuals after a single oral 300 mg dose.

References

1. Capparelli, EV, et al., & Connor, JD (2003). Pharmacokinetics and tolerance of zidovudine in preterm infants. The Journal of pediatrics 142(1) 47–52. DOI:10.1067/mpd.2003.mpd0335 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12520254

2. Zhou, XJ, et al., & Sommadossi, JP (1999). Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Antimicrobial agents and chemotherapy 43(1) 121–128. DOI:10.1128/AAC.43.1.121 PUBMED:https://pubmed.ncbi.nlm.nih.gov/9869576

3. Kasirye, P, et al., & Walker, AS (2012). Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1. Clinical pharmacology and therapeutics 91(2) 272–280. DOI:10.1038/clpt.2011.225 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22190066

Revisions

• 06/2025 initial generated model